Epoetin biosimilars in europe: Five years on

Advances in Therapy

Volumn 30, Issue 1, 2013, Pages 28-40

  Mikhail, Ashraf ^a   Farouk, Mourad ^b  

^a MORRISTON HOSPITAL   (United Kingdom)

^b AMGEN INC   (United States)

Author keywords

Anemia; Bioequivalence; Biosimilars; Chronic kidney disease; Epoetins; Erythropoietins; Pharmacovigilance

Indexed keywords

BIOSIMILAR AGENT; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; SB 309; SILAPRO; UNCLASSIFIED DRUG; ANTIANEMIC AGENT; ERYTHROPOIETIN; RECOMBINANT PROTEIN; DRUG DERIVATIVE;

AREA UNDER THE CURVE; AUTOIMMUNITY; BIOEQUIVALENCE; CLINICAL PHARMACOLOGY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EUROPE; GLYCOSYLATION; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOGENICITY; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS; OBSERVATIONAL STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; THERAPEUTIC EQUIVALENCE; ANALOGS AND DERIVATIVES; ANEMIA;

ANEMIA; BIOSIMILAR PHARMACEUTICALS; ERYTHROPOIETIN; EUROPE; HEMATINICS; HUMANS; PHARMACOVIGILANCE; RECOMBINANT PROTEINS; THERAPEUTIC EQUIVALENCY;

EID: 84884901120     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-012-0072-2     Document Type: Review

References (40)

1. Teuscher A. The history of insulin. In: Insulin - A Voice for Choice. Basel, Switzerland: Karger, 2007:10-13.
2. Giezen TJ, Mantel-Teeuwisse AK, Straus SM, Schellekens H, Leufkens HG, Egberts AC. Safetyrelated regulatory actions for biologicals approved in the United States and the European Union. JAMA. 2008;300:1887-96.
3. Schellekens H, Moors E. Clinical comparability and European biosimilar regulations. Nat Biotechnol. 2010;28:28-31.
4. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol. 2008;19:411-9.
5. Niederwieser D, Schmitz S. Biosimilar agents in oncology/haematology, from approval to practice. Eur J Haematol. 2011;86:277-88.
6. Schellekens H. The first biosimilar epoetin: but how biosimilar is it? Clin J Am Soc Nephrol. 2008;3:174-8.
7. Schellekens H. Recombinant human erythropoietins, biosimilars and immunogenicity. J Nephrol. 2008;21:497-502.
8. International Nonproprietary names for biological and biotechnological substances. World Health Organization website. Available at: http://www. who.int/medicines/services/inn/BioRevforweb.pdf. Accessed Nov 26 2012.
9. Schellekens H. Immunologic mechanisms of EPO- associated pure red cell aplasia. Best Pract Res Clin Haematol. 2005;18:473-80.
10. Nowicki M. Basic facts about biosimilars. Kidney Blood Press Res. 2007;30:267-72.
11. Greener M. Biosimilars: extending biologicals' benefits. European Industrial Pharmacy. 2009;3:9-11.
12. Guideline on similar biological medical products. Committee for Medicinal Products for Human Use, European Medicines Agency website. Available at: http://www.ema.europa.eu/docs/en-GB/ document-library/Scientific-guidelines/ 2009/09/ WC500003517.pdf. Accessed Nov 26 2012.
13. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant erythropoietins. Committee for Medicinal Products for Human Use, European Medicines Agency website. Available at: http://www.ema.europa.eu/docs/en-GB/ document-library/Scientific-guideline/ 2010/04/ WC500089474.pdf. Accessed on: Nov 26 2012.
14. Kiss Z, Elliott S, Jedynasty K, Tesar V, Szegedi J. Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa: an update of the rationale and clinical impact. Eur J Clin Pharmacol. 2010;66:331-40.
15. Epoetin alfa hexal European Public Assessment Report (EPAR) scientific discussion 2007. European Medicines Agency website. Available at: http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Scientific- Discussion/ human/000726/WC500028287.pdf. Accessed Nov 26 2012.
16. Brinks V, Hawe A, Basmeleh AH, et al. Quality of original and biosimilar epoetin products. Pharmaceutical Research. 2011;28:386-93.
17. Sörgel F, Thyroff-Friesinger U, Vetter A, Vens- Cappell B, Kinzig M. Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple IV administrations: an open-label randomised controlled trial. BMC Clin Pharmacol. 2009;9:10.
18. Sörgel F, Thyroff-Friesinger U, Vetter A, Vens- Cappell B, Kinzig M. Biosimilarity of HX575 (human recombinant epoetin alfa) and epoetin beta after multiple subcutaneous administration. Int J Clin Pharmacol Ther. 2009;47:391-401.
19. Haag-Weber M, Vetter A, Thyroff-Friesinger U; INJ- 9 Study Group. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin Nephrol. 2009;72:380-90.
20. Hörl WH, Locatelli F, Haag-Weber M, Ode M, Roth K; Epo-PASS study group. Prospective multicenter study of HX575 (biosimilar epoetin-I+/-) in patients with chronic kidney disease applying a target hemoglobin of 10-12 g/dl. Clin Nephrol. 2012;78:24-32.
21. Jelkmann W. Biosimilar epoetins and other follow- on biologics: update on the European experiences. Am J Hematol. 2010;85:771-80.
22. Seidl A, Hainzl O, Richter M, et al. Tungsten- induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm Res. 2012;29:1454-67.
23. Lissy M, Ode M, Roth K. Comparison of the pharmacokinetic and pharmacodynamic profiles of one US-marketed and two European-marketed epoetin alfas: a randomized prospective study. Drugs R D. 2011;11:61-75.
24. European Medicines Agency, Retacrit European Public Assessment Report (EPAR). Scientific discussion. 2007. European Medicines Agency website. Available at: http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR- Scientific- Discussion/human/000872/WC500054374.pdf. Accessed Nov 26 2012.
25. Singh SK. Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci. 2011;100:354-87.
26. Kirkov V, Dimitrova V, Siebert-Weigel M, et al. Evaluation of the pharmacokinetics of two recombinant human erythropoietin preparations: epoetin zeta and epoetin alfa. 1st communication: a monocentric, open, randomized, single dose, two-period crossover trial in healthy volunteers. Arzneimittelforschung. 2008;58:215-9.
27. Kirkov V, Dimitrova V, Siebert-Weigel M, et al. Evaluation of the pharmacokinetics of two recombinant human erythropoietin preparations: epoetin zeta and epoetin alfa. 2nd communication: a monocentric, double-blind, randomized, single dose, threeperiod crossover trial in healthy volunteers. Arzneimittelforschung. 2008;58:220-4.
28. Krivoshiev S, Todorov V, Manitius J, Scigalla P, Koytchev R; Epoetin Zeta Study Group. Comparison of the therapeutic effects of epoetin zeta and epoetin alfa in the correction of renal anaemia. Curr Med Res Opin. 2008;24:1407-15.
29. Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R; Epoetin Zeta Study Group. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Curr Med Res Opin. 2008;24:625-37.
30. Baldamus C, Krivoshiev S, Wolf-Pflugmann M, Siebert-Wiegel M, Koytchev R, Bronn A. Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Adv Ther. 2008;25:1215-28.
31. Wieçek A, Ahmed I, Scigalla P, Koytchev R. Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: posthoc analysis. Adv Ther. 2010;27:941-52.
32. Krivoshiev S, Wizemann V, Czekalski S; Epoetin Zeta Study Group. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia. Adv Ther. 2010;27:105-17.
33. Schellekens H. Biosimilars: the long and winding road to clinical equivalence. Hosp Pharm Eur. 2009;47. Hospital Pharmacy Europe website. Available at: http://www.hospitalpharmacyeurope. com/default.asp?title= Biosimilars%3A%5Fthe%5Fl ong%5Fand%5Fwinding%5Froad%5Fto%5Fclini cal%5Fequivalence&page=article.display&article. id=19174. Accessed Nov 26 2012.
34. Kuhlmann M, Marre M. Lessons learned from biosimilar epoetins and insulins. Br J Diabetes Vasc Dis. 2010;10:90-7.
35. Kerwin B, Smalling R, Deechongkit S, Swanson S. Questions remain about drug-induced PRCA: what hospital pharmacists need to know. EJHP-P. 2005;2:42-5. Available at: http://archive.eahp.eu/ Media/Home-page/EJHP-BMJ/EJHP-Practice- archive/ Issue-2-2005/Industry-science/Questions-Remain- About-Drug-induced- PRCA-What-Hospital- Pharmacists-Need-to-Know. Accessed Nov 26 2012.
36. Macdougall IC. Pure red cell aplasia with anti- erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another. Curr Med Res Opinion. 2004;20:83-6.
37. Boven K, Stryker S, Knight J, et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int. 2005;67:2346-53.
38. Praditpornsilpa K, Tiranathanagul K, Kupatawintu P, et al. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int. 2011;80:88-92.
39. 2010 pharmacovigilance legislation. Article 102e, Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010. Official Journal of the European Union 31.12.2010. European Medicines Agency website. Available at: http://www.ema.europa.eu/ema/ index.jsp?curl=pages/regulation/ general/general- content-000492.jsp. Accessed Nov 26 2012.
40. Questions and answers on biological medicines (similar biological medicinal products). European Medicines Agency website. Available at: http://www.ema.europa.eu/docs/en-GB/document- library/Medicine-QA/2009/12/ WC500020062.pdf. Accessed Nov 26 2012.